DEA Raises Psychedelics Quotas and Hints at Its Next Cannabis Step

A busy day of drug policy news centered on the Drug Enforcement Administration, which increased its quotas for psychedelics while also previewing an upcoming move on cannabis. The agency's quota decisions set limits on how much of certain controlled substances can be produced, so an increase for psychedelics is a notable signal for researchers and companies working in that space. The preview of a cannabis action has drawn even more attention, since federal decisions on marijuana policy can ripple through licensed businesses and consumers across the country.

Hemp was also in the spotlight. The Food and Drug Administration released its guidance on hemp later than expected, adding another piece to an area where producers and retailers have been waiting for clarity. Anyone who sells or makes hemp-derived products has a stake in how federal regulators choose to frame their expectations.

In Texas, attention turned to the prospects for marijuana reform following the latest elections, as advocates and lawmakers weigh what might be possible in the state going forward. Missouri regulators, meanwhile, issued a warning about interstate cannabis commerce. That is a reminder that even in states with legal markets, moving product across state lines remains prohibited, and licensees who ignore that risk can face serious consequences.

In North Carolina, an opinion piece on marijuana added to the discussion about where the state stands on cannabis, a topic that continues to draw debate.

Taken together, these developments show how many layers of cannabis policy are moving at once. Federal agencies are shaping the rules around scheduling, quotas, and hemp, while states are working through their own reform debates and enforcement priorities. For anyone who follows the industry, the DEA's preview of its cannabis plans is the item to watch, because federal action there could affect nearly everyone else on this list.